National Planning Corporation’s Vertex Pharmaceuticals VRTX Stock Holding History

National Planning Corporation’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-4,270	Closed	-$649K	–	610
2017 Q3	$649K	Sell	4,270 -218	-5%	-$32.8K	0.05%	309
2017 Q2	$575K	Sell	4,488 -125	-3%	-$15K	0.04%	370
2017 Q1	$518K	Hold	4,613	–	–	0.04%	374
2016 Q4	$400K	Hold	4,613	–	–	0.03%	425
2016 Q3	$384K	Buy	4,613 +126	+3%	+$11.9K	0.03%	418
2016 Q2	$445K	Sell	4,487 -300	-6%	-$25.9K	0.03%	400
2016 Q1	$409K	Sell	4,787 -301	-6%	-$27.2K	0.04%	401
2015 Q4	$441K	Buy	5,088 +1	+0%	+$121	0.04%	432
2015 Q3	$635K	Buy	5,087 +1	+0%	+$128	0.06%	296
2015 Q2	$691K	Hold	5,086	–	–	0.06%	282
2015 Q1	$621K	Sell	5,086 -412	-7%	-$49.4K	0.06%	298
2014 Q4	$663K	Buy	5,498 +86	+2%	+$9.69K	0.05%	328
2014 Q3	$588K	Buy	+5,412	New	+$515K	0.04%	357

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

National Planning Corporation's VRTX Position: Q4 2017 in Review

National Planning Corporation sold out of Vertex Pharmaceuticals (VRTX) in Q4 2017, closing a stake of 4,270 shares — an estimated $649K sold.

National Planning Corporation first reported a position in VRTX in Q3 2014 and held it in 13 quarters. The position peaked at $691K in Q2 2015. 644 funds tracked by Wall St. Rank hold VRTX as of Q4 2017.

National Planning Corporation reported no remaining Vertex Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
National Planning Corporation sold 4,270 Vertex Pharmaceuticals shares in Q4 2017, an estimated $649K.
National Planning Corporation first reported a position in Vertex Pharmaceuticals in Q3 2014 and held it in 13 quarters.
National Planning Corporation's Vertex Pharmaceuticals position peaked at $691K in Q2 2015.
644 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2017.

Based on National Planning Corporation's 13F filing for Q4 2017, filed 14 Feb 2018.